HF
ACHL

HRT Financial’s Achilles Therapeutics ACHL Stock Holding History

HRT Financial’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,942
Closed -$8K – 3310
2024
Q2 		$8K Sell
10,942
-25,976
-70% -$22.8K ﹤0.01% 2014
2024
Q1 		$46K Buy
+36,918
New +$39.8K ﹤0.01% 1941

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

HRT Financial's ACHL Position: Q3 2024 in Review

HRT Financial sold out of Achilles Therapeutics (ACHL) in Q3 2024, closing a stake of 10,942 shares — an estimated $8K sold.

HRT Financial first reported a position in ACHL in Q1 2024 and held it in 2 quarters. The position peaked at $46K in Q1 2024. 22 funds tracked by Wall St. Rank hold ACHL as of Q3 2024.

  • HRT Financial reported no remaining Achilles Therapeutics position as of Q3 2024 after selling out during the quarter.
  • HRT Financial sold 10,942 Achilles Therapeutics shares in Q3 2024, an estimated $8K.
  • HRT Financial first reported a position in Achilles Therapeutics in Q1 2024 and held it in 2 quarters.
  • HRT Financial's Achilles Therapeutics position peaked at $46K in Q1 2024.
  • 22 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q3 2024.

Based on HRT Financial's 13F filing for Q3 2024, filed 12 Nov 2024.